CLINICAL TRIALS PROFILE FOR SECTRAL

All Clinical Trials for SECTRAL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00578617 ↗	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	Abbott Medical Devices	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	Duke Clinical Research Institute	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	St. Jude Medical	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗	Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial	Completed	Mayo Clinic	N/A	2006-09-01	The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT01743885 ↗	Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma	Terminated	University Hospital, Montpellier	Phase 3	2012-11-01	There is no effective treatment for hemangioma regardless of immediate severity. That is in this respect a orphan disease. These hemangiomas, sometimes large, will have a phase of proliferation of several months (very scary for parents) and regression over several years. The natural history is peppered with local complications (ulcers) and aesthetic and psychological sequelae (sometimes major for the child and the family). The effects of acebutolol and propranolol on the proliferative hemangiomas were discovered accidentally by two French teams (Montpellier for acebutolol and Bordeaux for propranolol). Acebutolol and propranolol have been used for many years for the treatment of hypertension and congenital heart disease, including infants, with few side effects. The effects of acebutolol and propranolol were immediately visible with reduced volume and skin whitening of the hemangioma. In a preliminary study, acebutolol was administered to 20 patients in Montpellier with big regression of hemangiomas. The aim of the study was to compare the clinical efficacy of acebutolol (10mg/Kg/jour) and propranolol (3mg/Kg/j) on the proliferative phase of infantile hemangioma in infants.
NCT02853045 ↗	Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients	Completed	Centre Hospitalier Universitaire de Saint Etienne	Phase 4	2015-06-11	Despite a large diffusion for generic anti-hypertensive, they are not currently used. Clinical validation studies could be better to convince users and prescribers than pharmacologic validation only. A pragmatic study to evaluate generic anti-hypertensive efficacy is proposed. It takes place in real conditions of care for hypertensive patients, for a manometer control criteria. The aim of the study is to test the hypothesis of non-inferiority for generic anti-hypertensive for blood pressure control.

Clinical Trial Conditions for SECTRAL

Condition Name

Condition Name for SECTRAL
Intervention	Trials
Atrial Fibrillation	1
Hemangioma	1
Hypertension	1
Arrhythmia	1

Condition MeSH

Condition MeSH for SECTRAL
Intervention	Trials
Hypertension	1
Port-Wine Stain	1
Hemangioma, Capillary	1
Hemangioma	1

Clinical Trial Locations for SECTRAL

Trials by Country

Trials by Country for SECTRAL
Location	Trials
United States	10
France	2

Trials by US State

Trials by US State for SECTRAL
Location	Trials
Utah	1
Pennsylvania	1
Ohio	1
Minnesota	1
Massachusetts	1

Clinical Trial Progress for SECTRAL

Clinical Trial Phase

Clinical Trial Phase for SECTRAL
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for SECTRAL
Clinical Trial Phase	Trials
Completed	2
Terminated	1

Clinical Trial Sponsors for SECTRAL

Sponsor Name

Sponsor Name for SECTRAL
Sponsor	Trials
Duke Clinical Research Institute	1
St. Jude Medical	1
Mayo Clinic	1

Sponsor Type

Sponsor Type for SECTRAL
Sponsor	Trials
Other	4
Industry	2

Last updated: May 4, 2026

SECTRAL (Sectral, acebutolol): Clinical Trials Update, Market Analysis, and Projections

What is SECTRAL and how is it positioned clinically?

SECTRAL is the brand name for acebutolol, an oral, non-selective beta-blocker with intrinsic sympathomimetic activity. It is used for cardiovascular indications including arrhythmias and hypertension in multiple markets. Market access and clinical use remain anchored to older guideline pathways and generics penetration rather than to a late-stage, brand-led pipeline.

Key point for business planning: No new late-stage clinical development signal is evident from publicly available trial registries at a scale that would reset market expectations for the brand in the near term. Commercial outcomes are therefore primarily driven by label geography, formulary position, and generic competition.

---

What clinical trials activity is visible for SECTRAL (acebutolol)?

Public registries show routine, small-scale studies and observational work, but they do not show a brand-defining Phase 3 development program for SECTRAL in the way that would support a step-change in market size or pricing.

Current development pattern (high level):

• Predominantly older-data evidence base for acebutolol.
• Ongoing registry activity is more consistent with safety surveillance, utilization studies, or reformulation/biopharm work than with new efficacy moats.
• No clear, brand-linked Phase 2/3 readout timeline that would justify a major forecast revision.

Commercial implication: Clinical trial updates for SECTRAL are unlikely to create a near-term demand inflection. Demand is more sensitive to payer policy, generic supply, and physician switching behavior than to incremental clinical endpoints.

---

How does the market for acebutolol/SECTRAL work commercially?

SECTRAL competes in a mature beta-blocker class where generics dominate. Beta-blockers as a category are widely reimbursed, with prescribing decisions driven by:

• patient comorbidity profiles (arrhythmia patterns vs hypertension control),
• dose form and tolerability,
• historical prescriber preference,
• formulary tiering and net price after rebates.

Market structure characteristics:

• High generic substitution risk for acebutolol products.
• Brand differentiation is limited by the underlying pharmacology class and by the time since original approvals.
• Demand stickiness can persist in some geographies where clinicians historically used acebutolol for specific rhythm-control needs, but growth is constrained.

Brand-level outcome driver: Net sales for SECTRAL typically track market share vs generics and reimbursement intensity, not breakthrough clinical events.

---

Where does SECTRAL sell, and what does that imply for forecast shape?

Acebutolol brands tend to be concentrated in countries where the product is established and where beta-blocker prescribing supports older agents for certain patient cohorts. Forecasts for SECTRAL therefore usually assume:

• stable-to-declining unit share versus generics over time,
• modest volatility tied to patent/generic milestones in each jurisdiction,
• periodic reimbursement pressure.

Business planning implication: Expect gradual erosion of brand share absent a new evidence package or safety/efficacy differentiation that payers recognize.

---

What are the market drivers and headwinds for projection?

Drivers (what supports baseline demand):

• Long clinical history and entrenched use in selected arrhythmia/hypertension pathways.
• Oral beta-blocker adherence patterns favor continued therapy among existing users.
• Reimbursement stability for beta-blockers in many markets.

Headwinds (what limits upside):

• Generic dominance and price compression.
• Class-level prescribing shifts toward newer beta-blockers (where guidelines and outcomes data favor them).
• No clear brand-led late-stage program likely to expand indications or create premium positioning.

---

What is the projection for SECTRAL: baseline, downcase, and upside?

A rigorous projection requires jurisdiction-level sales, net pricing, share, and competitor supply. Those inputs are not provided in the request, and without them a complete numeric forecast would be speculative.

What can be projected with business utility from the publicly typical lifecycle of a mature branded beta-blocker is the directional outlook:

Directional market projection for SECTRAL (acebutolol):

• Next 12 to 24 months: stable to slight decline, driven by continued generic substitution.
• 24 to 48 months: gradual share erosion and net price pressure; sales growth is unlikely without a reimbursement improvement or a supply event.
• 48+ months: further compression unless a new label expansion or evidence package changes payer behavior.

Scenario logic (non-numeric):

• Baseline: gradual share erosion, flat category demand.
• Downcase: accelerated share shift due to stronger generics or formulary tightening.
• Upside: temporary resilience if a regional supply constraint or formulary reinstatement occurs, plus stable adherence among existing cohorts.

---

What should investors and R&D leaders watch in the clinical and regulatory stream?

Even without a brand-defining Phase 3 program, the following are the signals that matter:

• Registry signal: Any new Phase 2/3 interventional trial or randomized comparative study tied to acebutolol outcomes in relevant rhythm categories.
• Label changes: Any new country-specific indication updates or dosing form approvals that expand usage beyond established patterns.
• Safety monitoring updates: Signals that change prescribing constraints (for example, bradycardia or heart block thresholds).
• Bioavailability/formulation: Studies that affect generic substitutability and interchangeability (can shift real-world switching).
• Payer policy: Formulary tier movements and prior authorization changes for beta-blockers that can tilt share among agents.

---

Key Takeaways

• SECTRAL (acebutolol) is a mature branded beta-blocker exposed to high generic substitution risk.
• Publicly visible clinical activity does not indicate a near-term Phase 3 development program that would create an evidence-driven demand inflection.
• Market outcomes are forecast to be driven mainly by geography-specific net price, reimbursement, and brand share versus generics.
• Directionally, expectations are stable-to-declining sales over the next 1 to 4 years absent a label expansion or payer-relevant new clinical evidence package.

---

FAQs

1) Is SECTRAL currently supported by new Phase 3 outcomes that would expand the market?

No clear brand-defining Phase 3 program is evident in publicly visible clinical development patterns that would justify a major market expansion forecast.

2) What drives SECTRAL performance more than clinical trials?

Formulary status, net pricing versus generics, prescriber switching behavior, and patient retention on existing therapy.

3) What is the biggest commercial risk for SECTRAL?

Continued generic price compression and substitution that reduces brand share.

4) What would most likely create an upside scenario for SECTRAL?

A new evidence package that payers recognize, or a jurisdiction-level policy or supply event that delays generic substitution.

5) What clinical registry signals should be monitored going forward?

New interventional randomized studies, label-changing outcomes, and safety monitoring updates that affect real-world prescribing thresholds.

---

References

[1] FDA Drugs@FDA. SECTRAL (acebutolol) product information and labeling records.
[2] EMA. Assessment reports and EPAR-style documentation for acebutolol-containing products where available.
[3] ClinicalTrials.gov. Search results for acebutolol/SECTRAL-related trials.
[4] WHO ICTRP. International trial registry listings for acebutolol/related terms.
[5] PubMed. Peer-reviewed literature on acebutolol clinical use and comparative beta-blocker outcomes.